Chinese

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

Retrieved on: 
torsdag, maj 30, 2024
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Incidence, DNA, Plasma, MBC, Circulating tumor DNA, Helmy Eltoukhy, PIK3CA, Neoplasm, Nucleic acid thermodynamics, Chinese, Interim, Biomarker, ASCO, ESR1, Society, Liquid biopsy, ABC, Annual general meeting, Medical imaging

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.
  • Additional studies will present data supporting the application of genomic and epigenomic biomarkers in areas such as minimal residual disease detection and cohort characterization.
  • “The robust data we present at ASCO will further demonstrate the important scientific and clinical developments in cancer care that are possible using liquid biopsy,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO.
  • For more information and updates from the meeting, follow Guardant Health on LinkedIn and X (Twitter) or visit ASCO booth #28115.

MetaHomes Celebrates Art and Innovation with World-Renowned Light Painting Artist, Roy Wang

Retrieved on: 
onsdag, maj 22, 2024
Roy Wang, Partnership, System, Government, Chinese, Virtual reality, EB-5 visa, New media art, Artificial intelligence, Drug

DUBAI, United Arab Emirates, May 22, 2024 (GLOBE NEWSWIRE) -- On May 18, 2024, MetaHomes was honored to participate in the "Chinese Dragon" large-scale light painting creation event, hosted by world-renowned light painting artist Roy Wang, in Dubai. This collaboration added a touch of Chinese culture to Dubai's vibrant art landscape, further cementing MetaHomes' commitment to cultural integration and innovation.

Key Points: 
  • This collaboration added a touch of Chinese culture to Dubai's vibrant art landscape, further cementing MetaHomes' commitment to cultural integration and innovation.
  • MetaHomes' distinguished executives showed up in their numbers to witness the spectacular light painting creation and engage in in-depth exchanges with Roy Wang by actively participating in the light painting session.
  • The cooperation with Roy Wang, a luminary in the art world, not only introduced new cultural elements to MetaHomes but also enriched Dubai's vibrant art scene.
  • Jerry Wu, CEO of MetaHomes , commented on the event, "Collaborating with Roy Wang has been an incredible opportunity for MetaHomes.

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

Retrieved on: 
torsdag, maj 23, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Nucleic acid thermodynamics, Society, Abstract, McCormick Place, Liquid biopsy, Chinese, DNA, ASCO, Annual general meeting, MBC

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Points: 
  • Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the release of abstracts on alisertib to be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • The ASCO Annual Meeting will be held at McCormick Place in Chicago and online from May 31-June 4.
  • Abstract 1037: Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC 041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC)

Wolters Kluwer supports food-as-medicine research with enhanced nutrition-focused content

Retrieved on: 
torsdag, maj 16, 2024
Software, Research, Pharmaceutical, Data Management, Technology, Fitness & Nutrition, Science, Biotechnology, Alternative Medicine, Practice Management, Health, Diabetes, Pharmacology, Public, Wolters Kluwer, DSM-IV codes, Obesity, Ecosystem, Allergy, Mental health, Chinese, Publishing, Database, Senior, Trust, Medicine, Policy, Diet, Notifiable disease, Multimedia, Cognition, Record, Dietary supplement

Wolters Kluwer Health , in collaboration with International Food Information Service (IFIS Publishing), today announced the launch of an exclusive interdisciplinary health research database, Ovid Nutrition and Health (Ovid NutriHealth).

Key Points: 
  • Wolters Kluwer Health , in collaboration with International Food Information Service (IFIS Publishing), today announced the launch of an exclusive interdisciplinary health research database, Ovid Nutrition and Health (Ovid NutriHealth).
  • View the full release here: https://www.businesswire.com/news/home/20240516573261/en/
    Wolters Kluwer Health and the International Food Information Service launch an exclusive interdisciplinary health research database, Ovid Nutrition and Health (Photo: Business Wire)
    “The convergence of medicine and nutrition continues to be an important, growing trend in patient care and medical research.
  • The availability of verified, evidence-based nutritional medicine information for broader dissemination is crucial in addressing food-related health disparities,” said Rafael Sidi , Senior Vice President & General Manager of Health Research, Wolters Kluwer Health.
  • The collaboration between IFIS Publishing and Wolters Kluwer was built to meet the industry’s evolving information needs due to the growing focus on nutrition in medical education curricula and medical research.

Baxter Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication

Retrieved on: 
måndag, maj 13, 2024
Medical Supplies, Women, FDA, Baby, Maternity, Fitness & Nutrition, Biotechnology, General Health, Pharmaceutical, Consumer, Health, Patient, Oleic acid, Route of administration, Risk, Olive oil, Tubing (recreation), Parenteral nutrition, Soybean oil, Chinese, Growth, Baxter International, Malnutrition, U.S. FDA, Dietary supplement

Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.

Key Points: 
  • Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, today announced U.S. FDA approval of an expanded indication for Clinolipid (Lipid Injectable Emulsion) to be used in pediatric patients, including preterm and term neonates.
  • Clinolipid is Baxter’s proprietary mixed oil lipid emulsion that is used to provide calories and essential fatty acids in parenteral (intravenous) nutrition (PN) when oral or enteral nutrition is not possible, insufficient or contraindicated.
  • Clinolipid has been available in the U.S. for adults since 2019 and is now available for use in all ages.
  • Over the last several years, clinical practice has shifted away from using 100 percent soybean oil lipid emulsions – which was the standard of care for decades – to mixed lipid emulsions.

KIA AMERICA ANNOUNCES PRICING FOR 2025 SORENTO HYBRID

Retrieved on: 
måndag, maj 13, 2024
GDI, Chinese, Tax, Android Lollipop, Signature, Gasoline, Privacy, EPA, Google Play, MSRP, CarPlay, Photography, Android, SUV, Kia, HEV, Apple, Smartphone, Star chart, I-4, TFT, FWD, Torque, Kia Connect, Android Auto, Apple Inc., PHEV, Multimedia, NBA, OTA, Mobile phone

With an EPA-estimated 36 MPG combined7 (FWD models), the Sorento Hybrid is in it for the long haul.

Key Points: 
  • With an EPA-estimated 36 MPG combined7 (FWD models), the Sorento Hybrid is in it for the long haul.
  • For adventures outside of city limits, all-wheel drive8 is available on the Sorento Hybrid EX trim and standard on the SX-P.
  • Headquartered in Irvine, California, Kia America continues to top automotive quality surveys.
  • 6 Kia Digital Key requires an eligible Kia Connect subscription and a compatible smart device with an active data plan.

The Jason Foundation, Inc. Announces New Substance Use Disorder Awareness Initiative

Retrieved on: 
torsdag, maj 2, 2024
Education, Acadia Healthcare, CTC, Suds, Comprehensive, Partnership, Suicidal ideation, Chinese, Mental health, Substance abuse, Psychological abuse, Opioid, JFI, Nursing

HENDERSONVILLE, Tenn., May 2, 2024 /PRNewswire/ -- The Jason Foundation, Inc. (JFI) today announced the formation of a new initiative to raise awareness and provide information, tools, and resources to address substance use disorders (SUDs)/opioid use disorders (OUDs) and co-occurring mental health concerns that can lead to suicidal ideation.

Key Points: 
  • The initiative, the Phoenix Division, represents an affiliation between Acadia Healthcare's Comprehensive Treatment Center (CTC) Division and JFI.
  • The CTCs within the Acadia network provide medication-assisted treatment and personalized therapeutic interventions for adults who are struggling with addictions to opioids.
  • In communities throughout the United States, CTCs are playing a key role in the effort to end our nation's ongoing opioid epidemic.
  • You can find more information regarding the partnership on The Jason Foundation's website, https://jasonfoundation.com/phoenix-division/ .

Sovos Introduces Indirect Tax Suite to Meet Complexities of Global Compliance

Retrieved on: 
tisdag, april 30, 2024
Software, Networks, Accounting, Internet, Professional Services, Business, Fintech, Data Management, Apps, Applications, Technology, Data Analytics, Finance, Cloud, Organization, SUT, Risk, PEPPOL, ERP, GST, B2C, VAT, PDP, Chinese, Use tax, File, Intelligence, Consumption tax, Government, Indirect tax, Sales

Sovos , the always-on compliance company, introduces its Indirect Tax Suite, a comprehensive, integrated solution to modernize how companies meet global indirect tax obligations.

Key Points: 
  • Sovos , the always-on compliance company, introduces its Indirect Tax Suite, a comprehensive, integrated solution to modernize how companies meet global indirect tax obligations.
  • Part of the Sovos Compliance Cloud , the Indirect Tax Suite empowers enterprises to manage all of their indirect tax obligations with governments, buyers, suppliers and consumers.
  • “With the Sovos Indirect Tax Suite, companies can rely on the only comprehensive, global, always-on suite of integrated services in the industry to proactively manage compliance, benefiting from a single source of truth for tax data,” continued Akeroyd.
  • Global Determination: Sovos’ Global Tax Determination engine provides automated, accurate tax rates and rule updates for Sales and Use Tax (SUT), Value Added Tax (VAT) and Goods and Services Tax (GST) in 195 countries.

United States Liquid Biopsy Market Report 2023 and 2024-2032 Featuring Thermo Fisher Scientific, Roche Diagnostics, Bio-Rad, Biocept, Biocartis, Myriad Genetics, Exact Sciences, NeoGenomics, Quest - ResearchAndMarkets.com

Retrieved on: 
tisdag, april 23, 2024
Biotechnology, Surgery, Health, Genetics, Oncology, Liquid biopsy, Neoplasm, Nucleic acid thermodynamics, FDA, Urine, Breast cancer, CGP, NTRK, Prostate cancer, NIH, Woman, Blood, Entrectinib, Seminal vesicles, Gene, Liquid, Health care, Research, Plasma, Chinese, NGS, DNA, Lung, Incidence, Patient, Circulating tumor DNA, Diagnosis, Illumina, Inc., Biomarker, DCIS, NSCLC, Medical imaging

The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market Report by Cancer types, Products, Application, Biomarkers, Sample types, End-Users, and Company Analysis 2024-2032" report has been added to ResearchAndMarkets.com's offering.
  • The United States Liquid Biopsy Market value is foreseen to be around US$ 3.68 Billion by 2032.
  • These innovations enhance cancer detection and monitoring and propel the United States liquid biopsy market.
  • Breast cancer might stand out as a distinguished concern in the United States liquid biopsy market.

JUST IN TIME FOR THE PLAYOFFS, KIA'S IN-CAR NBA DISPLAY THEMES LET BASKETBALL FANS SHOWCASE TEAM SPIRIT

Retrieved on: 
torsdag, april 18, 2024
Gasoline, Display, EVP, Partnership, OTA, Photography, NBA, Golden State Warriors, Chicago Bulls, World Car Awards, Kia, Chinese, HEV, Kia Connect, SUV, EV9, PHEV, Video game

"This is just the tip-off, as we're committed to enhancing the ownership and driving experience with more exciting themes, collaborations, and digital features to be introduced in the future."

Key Points: 
  • "This is just the tip-off, as we're committed to enhancing the ownership and driving experience with more exciting themes, collaborations, and digital features to be introduced in the future."
  • The NBA display themes will be available for purchase for $39.99 for each team via the Kia Connect Store's Digital Features and Services, which is accessed through the Kia Access app or the Kia Owner Portal.
  • 2 Display Themes are only available on models that have the latest ccNC (Connected Car Navigation Cockpit) based infotainment system.
  • Once purchased, Display Themes are limited to use on the specific vehicle tied to purchase and cannot be transferred to other vehicles.